

Oncotarget
Oncotarget Podcast
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Episodes
Mentioned books

Aug 14, 2023 • 2min
Guiding Therapies for HPV Malignancies: Tumor Burden Surrogates
Researchers discuss the importance of using peripheral blood biomarkers to guide tailored therapies for advanced and metastatic HPV-associated malignancies, highlighting the significance of liquid biopsies in predicting treatment responses.

Aug 10, 2023 • 6min
Blog: Whole-Genome Doubling and Aneuploidy in Human Cancer
The podcast delves into the complex relationship between whole-genome doubling and aneuploidy in human cancers, highlighting their profound effects on cellular physiology, gene expression, and genome stability. Researchers discuss how WGD shapes the aneuploidy landscape of tumors, emphasizing the need for further research to understand their interactions and implications for tumor development and drug resistance.

Aug 9, 2023 • 3min
CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies
Researchers discuss the potential of CDK9 inhibitors in treating hematological malignancies by targeting cancer-promoting genes like MYC and MCL1. Preclinical studies show promising results, with enitociclib demonstrating clinical activity in high-grade B lymphoma patients. CDK9 inhibitors may offer synergistic effects when combined with other drugs in the treatment of these malignancies.

Aug 7, 2023 • 3min
AGO2 in T-prolymphocytic Leukemia (T-PLL)
Researchers delve into the challenges of treating T-Prolymphocytic Leukemia due to limited options and high relapse rates. Chromosomal aberrations and genomic alterations play a crucial role in the aggressive nature of this disease.

Aug 2, 2023 • 4min
Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors
Dr. Michael Goldstein discusses targeting H3K27me3 loss in pediatric brain tumors, particularly DMG, ependymoma, and medulloblastoma. High relapse rates in pediatric cancer challenge current treatments, with radiotherapy as a primary modality. H3K27 tri-methylation is a key epigenetic trait in these brain tumors. Exploring the role of H3K27-Me3 in treatment response and survival rates.

Aug 1, 2023 • 3min
Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)
Exploring the significance of ER expression in DCIS, a pivotal study showed lack of ER linked to 3-fold risk of recurrence. ER expression in DCIS is multi-clonal with important clinical implications. Some ER-positive DCIS cases also contained ducts lacking ER expression.

Jul 26, 2023 • 6min
Blog: The Obesity Paradox, Metformin and Lung Cancer
Exploring the link between obesity, diabetes, and lung cancer, scientists are investigating using Metformin to target all three issues. The podcast discusses the potential of Metformin's therapeutic properties and explores the obesity paradox in chronic illnesses and aging.

Jul 25, 2023 • 3min
KIAA0930: A Cachexic Phenotype Inducer in Cancer Cells
Exploring the potential therapeutic role of KIAA0930 in cancer cachexia, a new study identifies it as a candidate factor for inducing muscle atrophy in cancer cells, offering hope for developing anti-cachexia therapies

Jul 22, 2023 • 4min
A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells
New research paper on assessing p300/CBP in circulating tumor cells. Connection between SIRT2 deacetylation and p300 acetylation in prostate cancer. Use of Exclusion-based Sample Preparation to isolate CTCs. Staining optimization reveals expression of acetyl-p300 and acetyl-H3K18.

Jul 19, 2023 • 3min
Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4
Explore a new editorial paper discussing a novel therapeutic approach against melanoma by targeting Hedgehog signaling and BRD4. Learn about the limitations of current SMO inhibitors, the potential of non-canonical HH/GLI signaling, and the researchers' proposal for improving therapeutic response rates.